@article{f4dd8e082a8d4d3cb7405219c36ae557,
title = "A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution.",
abstract = "In 352 patients with primary open-angle glaucoma or ocular hypertension, a multicenter double-masked, parallel-group clinical study compared the effects on intraocular pressure and ocular comfort of 0.5% betaxolol ophthalmic solution, a cardioselective beta-adrenergic blocking agent, with 0.25% betaxolol suspension. With twice-daily dosages, baseline intraocular pressure was significantly reduced (P = .0005), with no significant difference between the two groups, at Week 2 and at Months 1, 2, and 3. Further, the prevalence of ocular discomfort upon topical instillation was significantly lower for 0.25% betaxolol suspension than for 0.5% betaxolol solution (P = .0005).",
author = "Weinreb, {R. N.} and Caldwell, {D. R.} and Goode, {S. M.} and Horwitz, {B. L.} and R. Laibovitz and Shrader, {C. E.} and Stewart, {R. H.} and Williams, {A. T.}",
note = "Funding Information: From the Department of Ophthalmology, University of California, San Diego, La Jolla, California (Dr. Weinreb); Tulane University Medical Center, New Orleans, Louisiana (Dr. Caldwell); Southwestern Medical School, Dallas, Texas (Dr. Goode); Houston, Texas (Dr. Horwitz); Austin, Texas (Dr. Laibovitz); Eye Clinic of Wichita, Wichita, Kansas (Dr. Shrader); Houston Eye Associates, Houston, Texas (Dr. Stewart); and Rocky Mountain Eye Center, Salt Lake City, Utah (Dr. Williams). This study was supported in part by Alcon Laboratories, Fort Worth, Texas.",
year = "1990",
month = aug,
day = "15",
doi = "10.1016/S0002-9394(14)76990-9",
language = "English (US)",
volume = "110",
pages = "189--192",
journal = "American journal of ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "2",
}